Clinical stage biotechnology company Adicet Bio Inc (Nasdaq: ACET) announced on Wednesday that it has received FDA approval to amend its Investigational New Drug (IND) application to include idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) in its ongoing Phase 1 trial for ADI-001.
Patient enrollment for these cohorts is set to begin in the first quarter of 2025. ADI-001's clinical development now targets six autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV).
Adicet plans to report initial data from its Phase 1 trial in the first half of 2025.
Alphyn doses first patient in Phase 2b trial of Zabalafin Hydrogel in Australia
Ananda Pharma's MRX1 receives ethics approval for Phase 1 study in Australia
Organon acquires US rights to TOFIDENCE from Biogen
Dupixent receives approval in Japan as first biologic for COPD treatment
Celltrion adds STEQEYMA to Costco Member Prescription Program
Alys Pharmaceuticals doses first patient in Phase IIa trial of ALY-101
Bio-Thera Solutions signs commercialisation and licence agreements with Dr. Reddy's Laboratories
Spyre Therapeutics starts dosing in Phase 1 clinical trial of SPY003
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Evommune enrols first patient in EVO301 Phase 2 trial
Revelation Biosciences reports Gemini's anti-inflammatory potential in PBMC study
Argent BioPharma announces positive CimetrA Phase IIb clinical trial results
Shilpa Medicare's Nor Ursodeoxycholic Acid Tablets IND receives regulatory approval in India
Gentian Diagnostics and Beckman Coulter launch calprotectin immunoassay